These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30229374)

  • 41. Economic Decision Model for First-Time Traumatic Patellar Dislocations in Adolescents.
    Nwachukwu BU; So C; Schairer WW; Shubin Stein BE; Strickland SM; Green DW; Dodwell ER
    Am J Sports Med; 2017 Aug; 45(10):2267-2275. PubMed ID: 28463547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.
    Alkhatib N; Sweitzer NK; Lee CS; Erstad B; Slack M; Gharaibeh M; Karnes J; Klimecki W; Ramos K; Abraham I
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):205-217. PubMed ID: 32710439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-utility analysis from a societal perspective.
    Johannesson M; O'Conor RM
    Health Policy; 1997 Mar; 39(3):241-53. PubMed ID: 10165464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies.
    Nord E
    Eur J Health Econ; 2018 Mar; 19(2):267-275. PubMed ID: 28258399
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index.
    Franklin M; Hunter RM; Enrique A; Palacios J; Richards D
    Value Health; 2022 Jun; 25(6):1018-1029. PubMed ID: 35667775
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experiment.
    Skedgel C; Wailoo A; Akehurst R
    Med Decis Making; 2015 Jan; 35(1):94-105. PubMed ID: 25145575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip.
    de Verteuil R; Imamura M; Zhu S; Glazener C; Fraser C; Munro N; Hutchison J; Grant A; Coyle D; Coyle K; Vale L
    Health Technol Assess; 2008 Jun; 12(26):iii-iv, ix-223. PubMed ID: 18513467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. QALYs and carers.
    Al-Janabi H; Flynn TN; Coast J
    Pharmacoeconomics; 2011 Dec; 29(12):1015-23. PubMed ID: 22077576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health care economic analyses and value-based medicine.
    Brown MM; Brown GC; Sharma S; Landy J
    Surv Ophthalmol; 2003; 48(2):204-23. PubMed ID: 12686305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Microdiscectomy Is More Cost-effective Than a 6-Month Nonsurgical Care Regimen for Chronic Radiculopathy.
    Glennie RA; Urquhart JC; Koto P; Rasoulinejad P; Taylor D; Sequeira K; Miller T; Watson J; Rosedale R; Bailey SI; Gurr KR; Siddiqi F; Bailey CS
    Clin Orthop Relat Res; 2022 Mar; 480(3):574-584. PubMed ID: 34597280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter?
    Tengs TO
    Value Health; 2004; 7(1):70-8. PubMed ID: 14720132
    [TBL] [Abstract][Full Text] [Related]  

  • 53. On the (not so) constant proportional trade-off in TTO.
    Attema AE; Brouwer WB
    Qual Life Res; 2010 May; 19(4):489-97. PubMed ID: 20151207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Equity-Efficiency Trade-offs Associated With Alternative Approaches to Deceased Donor Kidney Allocation: A Patient-level Simulation.
    Li B; Cairns JA; Johnson RJ; Watson CJE; Roderick P; Oniscu GC; Metcalfe W; Bradley JA; Tomson CR; Draper H; Forsythe JL; Dudley C; Ravanan R
    Transplantation; 2020 Apr; 104(4):795-803. PubMed ID: 31403554
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exploring a new method for deriving the monetary value of a QALY.
    Tilling C; Krol M; Attema AE; Tsuchiya A; Brazier J; van Exel J; Brouwer W
    Eur J Health Econ; 2016 Sep; 17(7):801-9. PubMed ID: 26289341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment.
    van de Wetering L; van Exel J; Bobinac A; Brouwer WB
    Pharmacoeconomics; 2015 Dec; 33(12):1289-300. PubMed ID: 26232199
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health technology assessment with risk aversion in health.
    Lakdawalla DN; Phelps CE
    J Health Econ; 2020 Jul; 72():102346. PubMed ID: 32592923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. QALYs and ambulatory status: societal preferences for healthcare decision making.
    Freath LL; Curry AS; Cork DMW; Audhya IF; Gooch KL
    J Med Econ; 2022; 25(1):888-893. PubMed ID: 35713217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.